Antares Pharma (ATRS) Tops Q2 EPS by 1c

Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $12.51 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform